IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EPT Disclosure

18 Jan 2006 11:17

Credit Suisse Securities (Eur) Ltd18 January 2006 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of exempt principal trader Credit Suisse Securities (Europe) Ltd Company dealt in Skyepharma Plc Class of relevant security to which the dealings Ordinary Sharesbeing disclosed relate (Note 1) Date of dealing 17 January 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities Highest price paid (Note Lowest price paid (Note 3)purchased 3) (GBP) (GBP) Total number of securities Highest price received Lowest price received (Notesold (Note 3) (GBP) 3) (GBP) 21,978 0.4450 0.4450 (b) Derivatives transactions (other than options) Product name, e.g. Long/short Number of securities Price per unit (Note 3)CFD (Note 4) (Note 5) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g. selling, securities price American, date money paid/call purchasing, to which (GBP) European receivedoption varying etc. the option etc. per unit relates (Note 3) (Note 5) (GBP) (ii) Exercising Product name, e.g. Number of Exercise price percall option securities unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. ..................................................................... None ..................................................................... Date of disclosure 18 January 2006Contact name Jenny LundquistTelephone number 020 7883 4332Name of offeree/offeror with which connected SkyePharma PlcNature of connection (Note 6) Connected party Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Sep 20122:31 pmRNSflutiform Launched in the UK
25th Sep 20128:00 amRNSTotal Voting Rights
25th Sep 20127:43 amRNSSubmission of New Drug Application in Japan
24th Sep 20122:53 pmRNSBond Proposals Approved
21st Sep 201210:02 amRNSflutiform Launched in Germany
18th Sep 201210:55 amRNSDirector/PDMR Shareholding
6th Sep 201210:26 amRNSHolding(s) in Company
4th Sep 20127:19 amRNSProduct Launch
23rd Aug 20127:00 amRNSRegulatory Approval
23rd Aug 20127:00 amRNSBondholder Agreement
23rd Aug 20127:00 amRNSHalf Yearly Report
8th Aug 20123:06 pmRNSHolding(s) in Company
7th Aug 20123:51 pmRNSDirector/PDMR Shareholding
27th Jul 20127:00 amRNSRAYOS (Lodotra) receives approval in U.S
17th Jul 20127:00 amRNSflutiform Receives Regulatory Approval in Germany
6th Jul 20129:25 amRNSDirector/PDMR Shareholding
3rd Jul 201211:26 amRNSRegulatory Approval
22nd Jun 20127:00 amRNSResearch Update
14th Jun 20129:56 amRNSDirector Declaration
7th Jun 20125:25 pmRNSDirector/PDMR Shareholding
16th May 20121:51 pmRNSResult of AGM
16th May 20127:00 amRNSInterim Management Statement
11th May 201210:35 amRNSDirector/PDMR Shareholding
27th Apr 20125:49 pmRNSHolding(s) in Company
27th Apr 201211:16 amRNSAnnual Information Update
23rd Apr 20123:39 pmRNSHolding(s) in Company
20th Apr 20122:23 pmRNSFlutiform Positive Outcome
20th Apr 20127:40 amRNSExparel $10m milestone payment
13th Apr 201210:29 amRNSAnnual Financial Report
11th Apr 20127:00 amRNSRespivert Contract
5th Apr 20123:36 pmRNSDirector/PDMR Shareholding
22nd Mar 20127:00 amRNSFinal Results
15th Mar 20124:44 pmRNSDirector/PDMR Shareholding
12th Mar 20127:00 amRNSNotice of Results
8th Feb 20129:00 amRNSNEW ORAL DEVELOPMENT ORGANISATION
3rd Feb 20125:28 pmRNSDirector/PDMR Shareholding
31st Jan 20128:30 amRNSDirectorate Change
10th Jan 201212:32 pmRNSDirector/PDMR Shareholding
10th Jan 20129:21 amRNSReorganisation of Swiss Operations
23rd Dec 20117:00 amRNSProduct Update
12th Dec 20115:09 pmRNSDirector Declaration
12th Dec 20113:39 pmRNSDirector/PDMR Shareholding
29th Nov 201112:16 pmRNSRegulatory Application
14th Nov 20117:00 amRNSInterim Management Statement
4th Nov 20114:15 pmRNSDirector/PDMR Shareholding
31st Oct 20112:41 pmRNSUS FDA approval of NDA for Exparel
21st Oct 20114:40 pmRNSSecond Price Monitoring Extn
21st Oct 20114:35 pmRNSPrice Monitoring Extension
18th Oct 20117:00 amRNSUPDATE ON FLUTIFORMT EUROPE
11th Oct 201110:26 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.